Neurocrine Biosciences Inc. (Nasdaq: NBIX) has announced that two more patents have been granted related to the company's proprietary Vesicular Monoamine Transporter 2 inhibitor, a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines, like dopamine, norepinephrine, serotonin and histamine, among nerve cells.
One patent, issued by the European Patent Office, covers chemical compositions, pharmaceutical compositions and uses of various compounds, including Neurocrine's Phase 2b clinical candidate NBI-98854. That patent has an expiration date of November 2027.
In addition to the already issued composition of matter patent, the U.S. Patent and Trademark Office also has granted a patent for NBI-98854, covering the method of treating hyperkinetic movement disorders. It also will expire in November 2027.
"This EU patent, coupled with our new United States methods of use patent, and the existing United States composition of matter patent provide a strong intellectual property estate around NBI-98854," said Kevin Gorman, CEO of Neurocrine Biosciences. "We intend to continue to expand our VMAT2 patent footprint on NBI-98854 and our other VMAT2 inhibitors in early development."
12790 El Camino Real
San Diego, CA 92130